Regorafenib & LorigerlimabRegorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT07071961

Conditions

Colorectal Cancer

Regorafenib

High Risk Patients

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Regorafenib (CT)

Lorigerlimab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-01. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-08-27.